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The glutathione S-transferases (GSTs) are a group of related
soluble detoxification enzymes which play an important role
in the protection of living cells from cytotoxic and
carcinogenic compounds (Jakoby, 1978). They catalyse the
conjugation of intracellular glutathione to reactive
electrophilic metabolites (including cytotoxic and
antineoplastic drugs) thereby protecting against damage to
macromolecules such as DNA, and can also reduce organic
peroxides, protecting the cell from oxidative stress. Thus
glutathione S-transferases have an important function in the
detoxification and repair of cellular injury caused by a
diverse range of antineoplastic and cytotoxic drugs,
including, for example, the alkylating agents
cyclophosphamide and melphalan, and the cytotoxic
antibiotics, mitomycin C and doxorubicin (Arrick & Nathan,
1984).
Chemotherapeutic drugs are in essence cytotoxic, the
rationalisation of their use in the treatment of neoplasia
being the toxicity of the drug(s) to normal tissues, relative to
tumour cells. Tumour cells can, however, develop resistance
to chemotherapeutic drugs, and often cells selected for
resistance to certain types of antineoplastic agents develop
cross-resistance to a variety of other structurally dissimilar
agents. While the mechanism(s) of such multidrug resistance
remain unclear, recent work has shown that in a doxorubicin
(adriamycin)-resistant human breast cancer cell line (which
also displays a multidrug resistance phenotype), resistance is
associated with the increased activity of a new anionic GST
isozyme, immunologically related to the enzyme found in
human placenta, GST-i (Batist et al., 1986).
GST-x (or GST-3) represents one of the five or so human
GSTs readily identifiable by starch gel electrophoresis
(Laisney et al., 1984). The tissue distributions of other
members of the family are quite specific and GST-x is the
only enzyme of the group to be expressed in all tissues
examined, including peripheral blood leucocytes (Laisney et
al., 1984).
The gene is evolutionarily conserved, and in rats its
analogue, GST-P or GST 7-7, has been identified as a
marker for preneoplastic cells of hepatocellular origin in
chemically induced rat liver tumours, whether induced by
rapid or long-term dosing regimens (Kitahara et al., 1984;
Satoh et al., 1985; Sugioka et al., 1985; Russel et al., 1988).
Interestingly, these preneoplastic cells are also known to
develop resistance to many structurally diverse hepatotoxins
(Farber, 1984). This strongly suggests that the induction of
high levels of this particular anionic form of GST in both
systems may be responsible for the cellular resistance and the
subsequent protection and growth of tumour cells in the
presence of cytotoxic agents, be they chemotherapeutic or
carcinogenic (Cowan et al., 1986).
Furthermore, increased levels of GST-x have been found
in primary human hepatomas (Soma et al., 1986) and
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substantial levels have been found in a range of human
tumours and tumour cell lines (Shea et al., 1988). GST-x
transcripts have also been shown to be elevated in primary
ureteric and bladder carcinomas (McQuaid et al., 1988).
Such observations may possibly have implications in the
ability of cells from such tumours to detoxify antineoplastic
drugs, and to the inherent or acquired resistance of these
neoplasms to chemotherapy.
As yet, little is known of the transcriptional activity of the
GST-i gene in human haematological malignancies. While
these conditions are generally amenable to cytotoxic drug
therapy, wide variations in the effectiveness of such agents
occur, with perhaps the monocytic leukaemias as a class
displaying the highest degree of resistance. We have
therefore set out to assess the steady state levels of GST-r
transcript in leucocytes from patients suffering from a
variety of leukaemias or preleukaemias before chemotherapy,
including monocytic, myeloblastic, lymphoblastic and
erythroleukaemia, as well as myelodysplastic syndromes.
While the majority of cases investigated displayed moderate
elevations (up to 3.2-fold) in levels of GST-x transcript,
systematic studies of mRNA levels in leucocytes from four
cases of leukaemia/lymphoma taken sequentially over a
period of several weeks following initiation of chemotherapy
showed dramatic reductions of transcript, arguing against a
significant role for GST-x as a major detoxifying agent of
cytotoxic drugs in peripheral leucocytes during the initial
stages of chemotherapy.
Total RNA was isolated from bone marrow and/or
peripheral leucocytes according to the method of Chirgwin et
al. (1979). Briefly, leucocytes were lysed in 4M guanidinium
isothiocyanate solution and the RNA separated from the
homogenate by ultracentrifugation through a 5.7 M CsCl
cushion. RNA pellets were resuspended in 0.5ml NTES
(0.1 M Tris.Cl, pH7.4, 50mM NaCl, 10mM EDTA, 0.2%
SDS) and precipitated with two volumes of ethanol. Rat
liver RNA was obtained by the hot phenol method as
described in Maniatis et al. (1982). Precipitated RNA was
subsequently stored at -20°C.
Total RNA was separated on denaturing agarose gels,
Northern blotted and hybridised with 32P labelled pGP5.
pGP5 is a cDNA clone containing the rat GST-P gene
(Suguoka et al., 1985) which shares high homology with the
human GST-i gene (Kano et al., 1987). Previously, pGP5
has been shown to cross-hybridise effectively with human
GST-x mRNA (McQuaid et al., 1988).
Figure 1 shows the resultant autoradiograph from a
Northern blot obtained with total leucocyte RNA from four
leukaemics (patients 6-9, Table I) and four normal controls,
hybridised with pGP5. A major transcript of 0.75Kb was
evident in all leucocyte RNAs, being the same size in
humans as in rat liver RNA (Suguoka et al., 1985; McQuaid
et al., 1988). Moderate elevations (up to 3.2-fold) in the
levels of GST-x mRNA were encountered in most cases of
malignancy (see Table I).
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Figure I Northern blot analysis of total leucocyte RNA from
normal and leukaemic individuals probed with pGP5. lOpg of
total RNA was electrophoresed through denaturing 1.5%
agarose MOPS/formaldehyde gel and Northern blotted on to
Hybond-N membranes (Amersham). Plasmid probes were nick-
translated (Rigby et al., 1977) to specific activities of
5-7 x 107 c.p.m. pg-1, using 32PdCTP. Northern blots were hy-
bridised and washed according to the manufacturer's instructions.
Final stringency washes were at IXSSC,42°C. Filters were auto-
radiographed using Fuji X-ray film and DuPont intensifying
screens for 24h. Lanes 1-4, total leucocyte RNA from leukaemic
patients nos 6-9, Table I, respectively. Lanes 5-8, total leucocyte
RNA from four normal individuals.
In order to evaluate further the possibility of fluctuations
in transcript levels in peripheral leucocytes following chemo-
therapy, total RNA was prepared from the circulating white
blood cells of two patients with leukaemia and two with
lymphoma, over a period of several weeks following
initiation of therapy. Details of patients selected, their
chemotherapeutic regimens, times of sampling during
treatment and levels of GST-r transcript relative to those
before therapy, as measured by densitometric scanning, are
shown in Table II.
Figure 2a shows an example of the Northern blot obtained
when total leucocyte RNA, taken from patient 3 (Table II)
at the time points indicated over the initial 12 days of
chemotherapy, was probed with pGP5. Total rat liver RNA
was also included on each filter. A major transcript of
0.75kb was detected in both the human leucocyte RNA and
rat liver RNA, the latter being the same size as previously
reported (Suguoka et al., 1985).
Initial pretreatment level of GST-i transcript were in all
cases quite evident, (e.g. Figure 2a, lane 2), but immediately
following initiation of treatment, levels of GST-i mRNA
very rapidly dropped to almost undetectable levels (e.g.
Figure 2a, lane 7 and Table II). This same pattern of
expression was found in all four patients selected.
To ensure that this effect as not due to the unequal
loading of RNA on gels or to the subsequent transfer on to
membranes, all filters were rehybridised with a murine 18S
ribosomal DNA probe, as shown in Figure 2b. In all cases,
all lanes gave equal hybridisation, therefore excluding these
possibilities
Furthermore, we examined whether the observed decrease
in GST-7r mRNA was due to the overall reduction of
transcription in peripheral leucocytes, perhaps as a result of
the cytotoxic effects of the agents used. Each filter was
therefore reprobed with a 7SKDNA probe, which is known
to be highly transcribed in vertebrate species (Humphries et
al., 1987). Figure 2c shows that, at all timepoints, the levels
ofthe leucocyte 7SK RNA remained constant. Further studies
would be required, however, particularly with genetic probes
detecting pol II transcripts, to determine the generality of
this observation.
Studies examining the effect of cyclophosphamide on
mouse bone marrow and peripheral circulation have shown
initial depletions in glutathione and glutathione transferase
levels (Carmichael et al., 1986). These initial depletions were
followed by raised glutathione and glutathione transferase
levels, which were shown by fluorescence activated cell
sorting to be restricted to an increased granulocyte
population (Carmichael et al., 1986). It is therefore plausible
that, in extended human chemotherapeutic regimens, similar
changes in cell population and glutathione transferase levels
may become evident.
The genomic sequences of both rat GST-P (Okuda et al.,
1987) and human GST-r (Cowell et al., 1988) have revealed
an 8bp motif upstream of the GST initiation start site. This
motif is identical to the consensus enhancer sequence
TGACTCAG found in the promoters of several genes
responsive to activation by the tumour promoter, TPA,
which include the human collagenase, methallothionein "IA
and interleukin 2 genes and the DNA tumour virus SV40
(Angel et al., 1987). This motif is known as TPA-
responsiveness element or TRE, and is remarkably similar to
the consensus sequence of c-Ha-ras inducible element (ras-
responsive element, RRE) found in the polyoma virus
enhancer (ImIer et al., 1988). Both TREs and RREs are
recognised and bound by the transcription factor AP-1
(Bohmann et al., 1987; Imler et al., 1988), the product of
the c-jun oncogene (Lamph et al., 1988). An inducible Ha-
Table I Levels of GST-r mRNA in leukaemic leucocyte RNA
Fold increase GST-rc
Patient Sex Diagnosis mRNA
I M Promyelocytic leukaemia 1.1
2 M Myelodysplastic syndrome 2.0
3 F Myelomonocytic leukaemia 2.3
4 F Myelomonocytic leukaemia 2.7
5 M Acute myeloblastic leukaemia 2.0
6 F Acute myeloblastic leukaemia 1.8
7 F Monocytic leukaemia 2.0
8 M Acute myeloblastic leukaemia 2.6
9 F Monocytic leukaemia 3.2
10 F Acute lymphoblastic leukaemia 1.9
11 F Myelodysplastic syndrome 2.2
12 F Erythroleukaemia 1.2
Levels of GST-r mRNA were measured by scanning densitometry of Northern
autoradiographs. Fold increases in leukaemia GST-r mRNA levels are given
relative to normal controls, where normal levels are designated as 1.542 S. McQUAID et al.
Table II Levels of GST-i mRNA in leukaemic/lymphoma leucocyte RNA during chemotherapy
Sex/age Diagnosis
F/36 Acute myeloid
leukaemia
M/14 Acute myeloid
leukaemia
F/19 Hodgkin's disease,
nodular sclerosing
stage ITEB
M/66 B-cell lymphoma,
large cell
right humerus
Chemotherapeutic
agents
Daunorubicin
Cytosine arabinoside
6-Thioguanine
Daunorubicin
Cytosine arabinoside
6-Thioguanine
Nitrogen mustard
Vincristine
Procarbazine
Prednisolone
Bleomycin
Doxorubicin
Cyclophosphamide
Vincristine
Prednisolone
Doses
given
85mg
170mg bid
170mg bid
50mg, 75mg
150mg bid
150mg bid
8.5mg
2mg
150mg
60mg
26mg, 17.5mg
80mg, 87.5mg
1.75g, Ig
2mg, 2mg
100mg, 180mg
Days of
treatment
1,3,5
1-10
1-10
I and 11
1-5, 11-15
1-5, 11-15
1 and 8
1 and 8
1-14
1-14
15 and 32
1 and 18
1 and 18
8 and 32
1-10, 18-22
Days of
samples
-2
2
4
7
11
14
16
21
3
5
10
18
3
5
8
10
12
1
4
6
8
11
14
19
34
36
Quantitation
of GST-7r mRNA (%)
100
49
31
<5
<5
<5
<5
<5
100
91
50
<5
<5
100
54
21
28
26
13
100
21
<5
<5
<5
<5
<5
<5
<5
Levels of GST-i mRNA were measured by scanning densitometry of Northern autoradiographs. Pretreatment levels of GST-7r mRNA are
given as 100%, with subsequent reductions in transcripts given relative to pretreatment levels.
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Figure 2 Northern blot analysis of total leucocyte RNA from patient 3 (Table II), taken before and during chemotherapy.
Northern analysis and hybridisation conditions were as described for Figure 1. Final stringency washes were at 1XSSC,42°C for a
and 0.IXSSC,42°C for b and c. Between rehybridisations, filters were boiled for 1 h on 0.1% SDS to remove previous probe. In
each panel, lane 1 is total rat liver RNA. Lane 2 is total human leucocyte RNA taken prior to chemotherapy. Lane 3 is total
human leucocyte RNA taken on day 3 of chemotherapy; lane 4 taken day 5; lane 5 taken day 8; lane 6 taken day 10; and lane 7
taken day 12; a shows total rat liver and total human leucocyte RNA probed with pGP5, a cDNA clone containing the rat GST-P
gene (Suguoka et al., 1985); b and c show the same filter as a reprobed with (b) a murine 18S ribosomal DNA probe and (c) a
genomic clone containing a 7SKRNA pseudogene (Humphries et al., 1987).
ras fusion gene, introduced into rat liver epithelial cells has
been shown to increase the steady state levels of GST-P (Li
et al., 1988) suggesting the possibility (Cowell et al., 1988)
that the tumour specific induction of GST-7r may be
mediated through a similar type of ras responsive
transcription, as ras mutations have been found in acute
myeloid leukaemias (Bos et al., 1985, 1987). preleukaemia
(Liu et al., 1987) and in myelodysplastic syndrome (Layton
et al., 1988).
With regard to reduction in levels of GST-7r transcript, it
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is possible that cytotoxic agents, such as those used in this
study, might interact directly or indirectly with the DNA
itself or with transcriptional factors in such a way as to
depress the overall rate of transcription of the GST-7t gene.
Whatever the mechanisms involved, the current data suggest
that while the transcriptional activation of the GST-i gene
may well be responsible for the increased resistance of
tumour cells maintained in vitro to cytotoxic drugs, this
phenomenon is unlikely to influence the rate of
detoxification or deactivation of antineoplastic agents in the
peripheral circulation of patients undergoing the initial
phases of chemotherapy, when the cytotoxic effects of such
agents are at a maximum.
We are gratefully indebted to Professor Masami Muramatsu for the
provision of the rat GST-P cDNA clone, pGP5 and to the Health
Research and Cancer Research Advancement Boards for their
generous support.
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